Evotec, Gladstone, Dolby Family Ventures deal

Evotec, Dolby and Gladstone’s for-profit arm, Cure Network Ventures Inc., partnered exclusively on a worldwide basis to discover and develop small molecules against microtubule-associated protein tau (tau; MAPT; FTDP-17) and an undisclosed ion channel to treat Alzheimer’s disease (AD). Gladstone will transfer IP related to the two programs to Cure Network Ventures, which will license the IP to Cure Network Dolby Acceleration Partners LLC, which Cure Network Ventures spun out in July to fund the two programs. ...